1887

Abstract

A murine model based on infection by the respiratory route has been used to study the pathogenesis of recombinant vaccinia viruses. The neurovirulent Western Reserve (WR) strain and the Wyeth smallpox vaccine strain were used as vectors. Recombinant viruses were constructed by insertion of the Epstein- Barr virus membrane glycoprotein 340 gene into the thymidine kinase (TK) gene of each vaccinia virus. Intranasal inoculation of DBA/2 mice with 10 pockforming units (pk.f.u.) of the WR strain was lethal but mice survived similar infection with the WR recombinant virus. Each virus was recovered from lung, blood and brain but, unlike wild-type virus, the recombinant virus was subsequently cleared. No deaths occurred after similar infection with the Wyeth strain or the Wyeth recombinant virus. There was limited growth of the Wyeth strain in the respiratory tract, low levels of virus in the blood and only sporadic recovery in brain extracts. The Wyeth recombinant virus was cleared rapidly with little viraemia or detectable infection of the central nervous system. No phenotypic character determined could be related consistently to the virulence of wild-type and recombinant viruses. Although the lethal character of the WR strain was affected by its TK phenotype, mice survived infection by intranasal inoculation with 10 pk.f.u. of WR TK+ recombinant viruses which either expressed the human interleukin 2 gene or had a deficient vaccinia virus growth factor gene.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-71-11-2761
1990-11-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/71/11/JV0710112761.html?itemId=/content/journal/jgv/10.1099/0022-1317-71-11-2761&mimeType=html&fmt=ahah

References

  1. Baxby D. 1974; A possible relationship between human pathogenicity of smallpox vaccines and virus growth at elevated temperatures. Journal of Hygiene 73:35–37
    [Google Scholar]
  2. Baxby D. 1975; Identification and interrelationships of the variola/vaccinia subgroup of poxviruses. Progress in Medical Virology 19:215–246
    [Google Scholar]
  3. Baxby D., Gaskell C. J., Gaskell R. M., Bennett M. 1986; Ecology of orthopoxviruses and use of recombinant vaccinia vaccines. Lancet ii:850–851
    [Google Scholar]
  4. Blancou J., Kieny M. P., Lathe R., Lecocq J. P., Pastoret P. P., Soulebot J. P., Desmettre P. 1986; Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature; London: 322373–375
    [Google Scholar]
  5. Boulter E. A., Appleyard G. 1973; Differences between extracellular and intracellular forms of poxviruses and their implications. Progress in Medical Virology 16:86–108
    [Google Scholar]
  6. Boursnell M. E. G., Foulds I. J., Campbell J. I., Binns M. M. 1988; Non-essential genes in the vaccinia virus HindIII K fragment: a gene related to serine protease inhibitors and a gene related to the 37K vaccinia virus major envelope protein. Journal of General Virology 69:2995–3003
    [Google Scholar]
  7. Briody B. 1959; Response of mice to ectromelia and vaccinia viruses. Bacteriological Reviews 23:61–95
    [Google Scholar]
  8. Brown F. 1990; Modem vaccines. From Jenner to genes - the new vaccines. Lancet i:587–590
    [Google Scholar]
  9. Buller R. M. L., Smith G. L., Cremer K., Notkins A. L., Moss B. 1985; Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature; London: 317813–815
    [Google Scholar]
  10. Buller R. M. L., Chakrabarti S., Cooper J. A., Twardzik D. R., Moss B. 1988; Deletion of the vaccinia growth factor gene reduces virus virulence. Journal of Virology 62:866–874
    [Google Scholar]
  11. Chua T. P., Smith C. E., Reith R. W., Williamson J. D. 1990; Inflammatory responses and the generation of chemoattractant activity in cowpox virus-infected tissues. Immunology 69:202–208
    [Google Scholar]
  12. Dalrymple J. M., Hasty S. E., Kakach L. L., Collett M. S. 1989; Mapping protective determinants of Rift Valley fever virus using recombinant vaccinia viruses. In Vaccines 89, Modem Approaches to New Vaccines Including the Prevention of Aids pp. 371–375 Lemer R. A., Ginsberg H., Chanock R. M., Brown F. Edited by New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  13. Dick G. 1966; Smallpox: a reconsideration of public health policies. Progress in Medical Virology 8:1–29
    [Google Scholar]
  14. Fenner F., Witter R., Dumbell K. R. 1989 The Orthopoxviruses San Diego: Academic Press;
    [Google Scholar]
  15. Flexner C., Hügin A., Moss B. 1987; Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature; London: 330259–262
    [Google Scholar]
  16. Gomwalk N. E., Healing T. D. 1981; Etomidate: a valuable anaesthetic for mice. Laboratory Animals 15:151–152
    [Google Scholar]
  17. Hirsch M. S., Nahmias A. J., Murphy F. A., Kramer J. H. 1968; Cellular immunity in vaccinia infection of mice. Antithymocyte serum effects on primary and secondary responsiveness. Journal of Experimental Medicine 128:121–132
    [Google Scholar]
  18. Jamieson A. T., Gentry G. A., Subak-Sharpe J. H. 1974; Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. Journal of General Virology 24:465–480
    [Google Scholar]
  19. John T. J. 1969; Properties of the CV1 strain of vaccinia virus. II. Studies in eggs and mice. Archiv für die gesamle Virusforschung 26:366–370
    [Google Scholar]
  20. Joklik W. K. 1962; The purification of four strains of poxvirus. Virology 18:9–18
    [Google Scholar]
  21. Kaplan C. 1989; Vaccinia virus: a suitable vehicle for recombinant vaccines?. Archives of Virology 106:127–139
    [Google Scholar]
  22. Karupiah G., Coupar B. E. H., Andrew M. E., Boyle D. B., Phillip S. M., Müllbacher A., Blanden R. V., Ramshaw I. A. 1990; Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2. Journal of Immunology 144:290–298
    [Google Scholar]
  23. Kempe C. H. 1968; Smallpox vaccination of eczema patients with attenuated live vaccinia virus. Yale Journal of Biological Medicine 41:1–12
    [Google Scholar]
  24. Koszinowski U., Thomssen R. 1975; Target cell-dependent T cell- mediated lysis of vaccinia infected cells. European Journal of Immunology 5:245–251
    [Google Scholar]
  25. Kotwal G. J., Moss B. 1988; Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature; London: 335176–178
    [Google Scholar]
  26. Kotwal G. J., Moss B. 1989; Vaccinia encodes two proteins that are structurally related to members of the plasma serine protease superfamily. Journal of Virology 63:600–606
    [Google Scholar]
  27. Lane J. M., Ruben F. L., Neff J. M., Miller J. D. 1969; Complications of smallpox vaccination, 1968. National surveillance in the United States. New England Journal of Medicine 281:1201–1208
    [Google Scholar]
  28. Mccarthy K., Dumbell K. R. 1961; Chorioallantoic inoculation of eggs, an improved method. Virology 14:488–492
    [Google Scholar]
  29. Mackett M., Arrand J. R. 1985; Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO Journal 4:3229–3234
    [Google Scholar]
  30. Mackett M., Yilma T., Rose J. K., Moss B. 1985; Vaccinia virus recombinants: expression of VSV genes and protective immunization of cattle. Science 221:433–435
    [Google Scholar]
  31. Morgan A. J., Mackett M., Finerty S., Arrand J. R., Scullion F. T., Epstein M. A. 1988; Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cotton- top tamarins against EB virus-induced lymphomas. Journal of Medical Virology 25:189–195
    [Google Scholar]
  32. Murphy B. R., Collins P. L., Chanock R. M., Prince G. A. 1989; Intranasal immunization with vaccinia-RS virus recombinant viruses is superior to intradermal immunization in animals with passively acquired antibodies. In Vaccines 89, Modern Approaches to New Vaccines Including the Prevention of Aids pp. 501–505 Lerner R. A., Ginsberg H., Chanock R. M., Brown F. Edited by New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  33. Needham J. 1980 China and the Origins of Immunology University of Hong Kong: Centre of Asian Studies;
    [Google Scholar]
  34. Osborn J. G. E., Chesters P. M., Williamson J. D. 1984; Arginine metabolism in infected cell cultures as a marker character for the differentiation of orthopoxviruses. Journal of Hygiene 93:213–223
    [Google Scholar]
  35. Palumbo G. J., Pickup D. J., Fredrickson T. N., Mcintyre L. J., Buller R. M. L. 1989; Inhibition of an inflammatory response is mediated by a 38-kDa protein of cowpox virus. Virology 172:262–273
    [Google Scholar]
  36. Payne L. G. 1980; Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. Journal of General Virology 50:89–100
    [Google Scholar]
  37. Pickup D. J., Ink B. S., Hu W., Ray C. A., Joklik W. K. 1986; Hemorrhage in lesions caused by cowpox virus is induced by a viral protein that is related to plasma protein inhibitors of serine proteases. Proceedings of the National Academy of Sciences, U.S.A 83:7698–7702
    [Google Scholar]
  38. Smith G. L., Howard S. T., Chan Y. S. 1989; Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. Journal of General Virology 70:2333–2343
    [Google Scholar]
  39. Townsend A., Bastin J., Bodmer H., Brownlee G., Davey J., Gotch F., Gould K., Jones I., Mcmichael A., Rothbard J., Smith G. 1989; Recognition of influenza virus proteins by cytotoxic T lymphocytes. Philosophical Transactions of the Royal Society, London, B 323:527–533
    [Google Scholar]
  40. Turner G. S. 1967; Respiratory infection of mice with vaccinia virus. Journal of General Virology 1:399–402
    [Google Scholar]
  41. Weir J. P., Moss B. 1983; Nucleotide sequence of vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutants. Journal of Virology 46:530–537
    [Google Scholar]
  42. Williamson J. D., Reith R. W., Arrand J. R., Mackett M. 1988; Attenuation of recombinant vaccinia viruses. In Technological Advances in Vaccine Development, UCLA Symposia on Molecular and Cellular Biology 84 pp. 205–214 Lasky L. Edited by New York: Alan R. Liss;
    [Google Scholar]
  43. Yilma T., Hsu D., Jones L., Owens S., Grubman M., Mebus C., Yamanaka M., Dale B. 1988; Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science 242:1058–1061
    [Google Scholar]
  44. Zagury D., Bernard J., Cheynier R., Desportes I., Leonard R., Fouchard M., Reveil B., Ittele D., Lurhuma Z., Mbayo K., Wane J., Salaun J.-J., Goussard B., Dechazal L., Burny A., Nara P., Gallo R. C. 1988; A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature; London: 332728–731
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-71-11-2761
Loading
/content/journal/jgv/10.1099/0022-1317-71-11-2761
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error